---
title: "Etretinate - Psoriasis"
sidebar: mydoc_sidebar
permalink: db00926-mesh-d011565-1.html
toc: false 
---


Path ID: `DB00926_MESH_D011565_1`
{% include image.html url="images/db00926-mesh-d011565-1.png" file="db00926-mesh-d011565-1.png" alt="db00926-mesh-d011565-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:D005050 | Etretinate | Drug |
| UniProt:P10276 | Retinoic acid receptor alpha | Protein |
| UniProt:P10826 | Retinoic acid receptor beta | Protein |
| UniProt:P19793 | Retinoic acid receptor RXR-alpha | Protein |
| UniProt:P48443 | Retinoic acid receptor RXR-gamma | Protein |
| GO:0031424 | Keratinization | BiologicalProcess |
| GO:0010481 | Epidermal cell division | BiologicalProcess |
| MESH:D011565 | Psoriasis | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Etretinate | INCREASES ACTIVITY OF | Retinoic Acid Receptor Alpha |
| Etretinate | INCREASES ACTIVITY OF | Retinoic Acid Receptor Beta |
| Etretinate | INCREASES ACTIVITY OF | Retinoic Acid Receptor Rxr-Alpha |
| Etretinate | INCREASES ACTIVITY OF | Retinoic Acid Receptor Rxr-Gamma |
| Retinoic Acid Receptor Alpha | NEGATIVELY REGULATES | Keratinization |
| Retinoic Acid Receptor Rxr-Alpha | NEGATIVELY REGULATES | Keratinization |
| Retinoic Acid Receptor Beta | NEGATIVELY REGULATES | Keratinization |
| Retinoic Acid Receptor Rxr-Gamma | NEGATIVELY REGULATES | Keratinization |
| Retinoic Acid Receptor Alpha | NEGATIVELY REGULATES | Epidermal Cell Division |
| Retinoic Acid Receptor Rxr-Alpha | NEGATIVELY REGULATES | Epidermal Cell Division |
| Retinoic Acid Receptor Beta | NEGATIVELY REGULATES | Epidermal Cell Division |
| Retinoic Acid Receptor Rxr-Gamma | NEGATIVELY REGULATES | Epidermal Cell Division |
| Keratinization | POSITIVELY CORRELATED WITH | Psoriasis |
| Epidermal Cell Division | POSITIVELY CORRELATED WITH | Psoriasis |
|---------|-----------|---------|

Comment: Withdrawn. Etretinate was taken off the market in Canada in 1996 and America in 1998 due to the risk of birth defects. Etretinate is now used to treat T-cell lymphomas.

Reference: 
  - [https://go.drugbank.com/drugs/DB00926](https://go.drugbank.com/drugs/DB00926)
